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Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56 S23CD69þCD4þ T cells in adipose tissue (r¼0.470, p¼0.27). Co-staining for
different cytokines upon polyclonal stimulation revealed that IL-6-
secreting CD4þ T cells are distinct from the T cells secreting other
cytokines such as IFNg and TNFa. In addition, chemokine receptor
expression revealed that these IL6 producing T cells could not be
categorized as conventional T helper 1 (Th1), Th2, Th17 or Tfh cells.
These data indicate that IL6-secreting T cells are a distinct population of
T cells. Finally, we have also studied whether these IL6 producing T cells
are also present in other tissues. Indeed, we have found these cells also
in sc adipose tissues and synovium of OA patients, but only at low
frequencies in blood.
Conclusions: In conclusion, we have found a novel population of CD4þ
T cells which secrete IL-6 directly ex vivo and are in an activated state,
indicating that these CD4þ T cells might recognize adipose tissue anti-
gens and could be involved in the inﬂammatory processes present in
human adipose tissue. Moreover, they are a source of IL-6 in the OA
joint, thereby potentially contributing to joint inﬂammation.
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INDUCTION OF NERVE GROWTH FACTOR EXPRESSION AND RELEASE
BY MECHANICAL AND INFLAMMATORY STIMULI IN CHONDROCYTES:
POSSIBLE INVOLVEMENT IN OA PAIN
E. Pecchi y,z, S. Priam y,z, M. Gosset y,z, A. Pigenet y,z, L. Sudre y,z,
M.-C. Laiguillon y,z, F. Berenbaum y,x, X. Houard y,z. y INSERM UMRS938,
Paris, France; zUPMC Univ Paris 06, Paris, France; xDept. of Rheumatology,
AP-HP Saint-Antoine Hosp., Labex Transimmunom, Inﬂammation-
Immunopathology-Biotherapy Dept. (I2B), Paris, France
Purpose: Nerve growth factor (NGF) level is increased in OA joint and is
involved in pain associated with OA. Stimuli responsible for NGF stim-
ulation in chondrocytes are unknown. We investigated whether
mechanical stress and pro-inﬂammatory cytokines may inﬂuence NGF
synthesis by chondrocytes.
Methods: Primary cultures of human OA chondrocytes, newborn
mouse articular chondrocytes or cartilage explants were stimulated by
increasing amounts of IL-1b, prostaglandin E2 (PGE2), visfatin/NAMPT
(nicotinamide phosphoribosyltransferase) or by cyclic mechanical
compression (0.5 Hz, 1 MPa). Before stimulation, chondrocytes were
pretreated with indomethacin, Apo866, a speciﬁc inhibitor of NAMPT
enzymatic activity, or transfected by siRNA targeting visfatin/NAMPT.
mRNA NGF levels were assessed by real-time quantitative PCR and NGF
released into media was determined by ELISA.
Results: Unstimulated human and mouse articular chondrocytes
expressed low levels of NGF (19.2  8.7 pg/mL, 13.5  1.0 pg/mL and 4.4
 0.8 pg/mL/mg tissue for human and mouse articular chondrocytes
and costal explants, respectively). Mechanical stress induced NGF
release in conditioned media. When stimulated by IL-1b or visfatin/
NAMPT, a pro-inﬂammatory adipokine produced by chondocytes in
response to IL-1b, a dose-dependent increase in NGF mRNA expression
and NGF release in both human and mouse chondrocyte conditioned
media was observed. Visfatin/NAMPT is also an intracellular enzyme
acting as the rate-limiting enzyme of the generation of NAD. The
expression of NGF induced by visfatin/NAMPTwas inhibited by Apo866,
whereas IL-1b-mediated NGF expression was not modiﬁed by siRNA
targeting visfatin/NAMPT. Interestingly, PGE2, which is produced by
chondrocytes in response to IL-1b and visfatin/NAMPT, did not stim-
ulate NGF production. Consistently, indomethacin, a cyclooxygenase
inhibitor, did not counteract IL-1b-induced NGF production.
Conclusions: These results suggest that the overexpression of visfatin/
NAMPT and IL-1b in OA joint and the increased mechanical loading of
cartilage may mediate OA pain via the stimulation of NGF expression
and release by chondrocytes.
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THE IMMUNOMODULATORY PROPERTIES OF MESENCHYMAL
STROMAL CELLS ISOLATED FROM THE SYNOVIAL FLUID OF HUMAN
OSTEOARTHRITIC JOINTS
N. Maillard, Jr. y,z, A. Cikankowitz, Jr. y, G. Grimandi, Sr. y,z,
O. Gauthier, Sr. y,x, S. Brouard, Sr. k,z, J. Guicheux, Sr. y,z,
N. Degauque, Jr. z,k, C. Vinatier, Jr. y. y INSERM UMRS 791, LIOAD, Research
Center for Osteoarticular and Dental Tissue Engineering, Nantes, France;
zUniv. Hosp., Nantes, France; xONIRIS, Coll. of Vet. Medecine, Nantes,
France; k INSERM UMRS 1064, ITUN, Nantes, FrancePurpose: OA is a degenerative joint disease accompanied by inﬂam-
mation, loss of cartilaginous matrix, ﬁbrillation, formation of ﬁssures,
and ultimately complete loss of the cartilage surface. Current pharma-
cological therapies for OA provide, at best, symptomatic relief from pain
but fail to prevent cartilage damage and subsequent destruction of
other joints tissues. Facing this situation, Mesenchymal Stromal Cells
(MSC) have generated a recent signiﬁcant medical consideration since
they have the ability to differentiate into various tissues (including
cartilage, bone, fat.) and exhibit tissue-regenerative properties.
Moreover, MSC display immunomodulatory properties that can be
instrumental for the treatment of inﬂammation-associated OA symp-
toms. Whereas adherent cells from the synovial ﬂuid (SFAC) of osteo-
arthritic joints have been proposed to meet the criteria of MSC (Jones,
English et al. 2004), their immunomodulatory properties have not yet
been characterized. With respect to the potential interest of isolating
some multipotent and immuno-competent cells from OA joints, the
present work aims at comparing the immunomodulatory properties of
SFAC with those of MSC isolated from bone marrow (BM-MSC) and
adipose tissue (ASC).
Materials and methods: Human BM-MSC and ASC were obtained from
healthy volunteers and human SFAC were harvested from OA patients
undergoing knee surgery, after consent. Flow cytometric (FACS) analysis
was performed to evaluate the expression of surface markers (CD14,
CD34, CD 44, CD 45, CD73, CD90, CD 105, CD166, HLA-ABC, HLA-DR) in
BM-MSC, ASC and SFAC. SFAC were characterized for their ability to
form colony by CFU-F assay andmultipotency. Themultipotency of SFAC
was characterized by evaluating their ability to differentiate towards
the adipogenic, osteogenic and chondrogenic lineage under speciﬁc
inductive culture conditions. Cell differentiation was monitored at the
level of mRNA by real time-PCR (ALPL, RUNX2, COL1A1, COL2A1, ACAN,
SOX9, COMP, PPARg) and by speciﬁc biochemical analysis: alkaline
phosphatase (ALP) activity and immunohistochemical staining: oil red
O, alizarin red, alcian blue and type II collagen. For immunomodulation
experiments, human allogeneic T lymphocytes were collected and co-
cultured with the various MSC. MSC were stimulated or not, prior to co-
culture, with Interferon g (IFN-g) and then analyzed by FACS for the
expression of HLA-ABC and HLA-DR. Proliferation and IFN-g secretion
by T lymphocytes were measured by FACS after co-culture of MSC and T
lymphocytes with different increasing ratios.
Results: SFAC were positive for MSC surface markers and negative for
hematopoietic cell markers. SFAC also exhibited proliferation and col-
ony-forming abilities. Additionally, SFAC were able to differentiate
towards the chondro-, osteo- and adipogenic lineages. Human T lym-
phocytes were not activated by MSC regarding proliferation and IFN-g
secretion suggesting that MSC failed to exhibit immuno-stimulating
properties. When cultured with activated T lymphocytes, MSC were
able to decrease IFN-g secretion by CD4þ and CD8þT lymphocytes and
inhibited their proliferation in a dose-dependent manner. Pre-stim-
ulation of MSC with IFN-g results in an increase in their immuno-reg-
ulatory properties. Data generated with SFAC were comparable to those
obtained with BM-MSC and ASC highlighting that SFAC exhibited
immuno-modulatory properties.
Conclusion: Our results demonstrate that the synovial ﬂuid of OA joints
contains a very accessible population of multipotent MSC. Our data also
indicate that SFAC exhibit immunosuppressive properties making
synovial ﬂuid a promising cell source for cell therapy in osteoarthritis.
Further experiments are under investigation with an increased number
of patients (clinical trial “Arthrostem” NCT01879046) to identify the
molecular mechanisms involved in the immunomodulatory properties
of SFAC.
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IDENTIFICATION OF SYNOVIAL GENES AND PATHWAYS ASSOCIATED
WITH DISEASE PROGRESSION IN A COHORT OF EARLY
OSTEOARTHRITIS PATIENTS (CHECK)
A.B. Blom y, P. van Lent y, M. van den Bosch y, H. Cats z,
F. van den Hoogen y,z, F. Lafeber x, P. van der Kraan y, W. van den Berg y.
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Purpose: Over 50% of osteoarthritis (OA) patients show synovial
inﬂammation, even relatively early during the disease. However, if and
how this synovial activation contributes to the irreversible joint path-
ology that characterizes OA, is not known. In the present study we used
Figure 1. Network of different placebo comparisons.
Figure 2. Standardized mean differences of active treatments for pain at
12 weeks comparing results from differential placebo effect network and
Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56S24microarray analysis of unique synovial tissue samples of early OA
patients and of experimental OA, to identify common pathways that
may determine progression of cartilage damage in this disease.
Methods: From a subpopulation of patients (n¼ 25) that entered the
CHECK Cohort study (Cohort Hip and Cohort Knee) and 6 controls,
synovial biopsies from the knee joint were collected at baseline and 2
and 5 years after inclusion. CHECK is a prospective 10-year follow-up
study on participants with early osteoarthritis-related complaints ini-
tiated by the Dutch Arthritis Association. Patients that entered the
cohort suffered from knee and/or hip pain and did not see a general
practitioner because of these complaints, longer than 6 months before
inclusion. At baseline and follow-up, highly standardized radiographs
were taken, and analyzed using the KIDA (Knee Image Digital Analysis)
system. Progression of joint damage was determined based on joint
space width and osteophyte formation. Synovial samples from baseline
were analysed using histology and affymetrix U133-plus-2.0 chips.
Analysis of microarray datawas performed using Partek Genomics Suite
software and functional annotation clustering (FAC) and pathway
analysis was done using DAVID.
Results: Upon histological examination at baseline, we found that lin-
ing thickness and synovitis were enhanced in the CHECK biopsies
compared to control synovia. Gene expression proﬁles of control
synovia were compared to our unique set of CHECK synovia. FAC
analysis indicated enrichment of several biological processes and sig-
naling pathways, including regulation of macrophage differentiation,
innate immune responses, cell migration, TGFb-, BMP- and wnt-sig-
naling. This indicates activation of the synovium in the CHECK patients
compared to controls. Next we compared synovial tissue taken at
baseline of CHECK-patients with radiological damage (KL1) with
CHECK-patients without joint damage (KL¼0) at baseline. Among the
genes that were strongest associated with cartilage damagewere MMP-
1 (18-fold), MMP-3 (10-fold), and S100A8 (6-fold). Immunohis-
tochemical staining revealed that expression of MMP-1 andMMP-3was
highest in the synovial lining layer. FAC analysis showed that chemo-
taxis, innate immune response and metalloproteases and pathways like
the complement-activation pathway were signiﬁcantly enriched and
thus associated with joint damage at baseline. To determine whether
any of the regulated genes and pathways were predictive for pro-
gression of joint damage between baseline and t¼5, we identiﬁed 13
patients that weremarked progressors and 8 non-progressors, based on
JSW and osteophyte size at these time points. At baseline, neither
minimum JSW nor osteophyte size differed between the groups.
Approximately 200 genes were expressed more than 2-fold higher in
synovium of progressors, versus non-progressors. Among these genes
were genes from the wnt-signaling pathway: WISP1, Fzd1, Fzd8 and
Fzd10, whereas FrzB was downregulated. Also inﬂammatory factors,
like IL-1, IL-6, S100A9, complement components C4a and CFI, and FN1
were more than 2-fold increased, as was MMP-1. In addition, macro-
phagemarkers like CD14, MHC class II genes, scavenger receptor A3 and
Cxcr2 were positively associated with progression. This indicates that
expression of these factors may predict, or even be involved in, pro-
gression of joint damage in OA patients. Using FAC we identiﬁed
inﬂammatory response, macrophage differentiation, blood vessel for-
mation, ossiﬁcation and cell migration to be enriched in patients that
show progression of damage 5 years later. Histologically, the pro-
gressors showed a higher thickness of the lining layer compared to non-
progressors, 2.0 vs 1.2 respectively on an arbitrary scale. No differences
were found on other parameters like synovitis and villi formation.
Conclusions: All in all, these data suggest an active role for the syno-
vium in OA pathology, and identiﬁes pathways that are likely to be
involved. We identiﬁed genes that are involved in the inﬂammatory
response and may be predictive for progression of OA. From histology
and the expression data, it appears that presence of macrophages,
especially in the lining layer, is associated with progression of joint
damage in OA. In addition, synovial expression of wnt-signaling genes
seems important in progression of damage as well.
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DIFFERENTIAL RESPONSE OF PLACEBO TREATMENTS IN
OSTEOARTHRITIS TRIALS: A SYSTEMATIC REVIEW AND NETWORK
META-ANALYSIS
R.R. Bannuru y, C.H. Schmid z, M.C. Sullivan y, D.M. Kent y, J.B. Wong y,
T.E. McAlindon y. y Tufts Med. Ctr., Boston, MA, USA; zBrown Univ.,
Providence, RI, USAPurpose: Placebo controls are essential when evaluating the effective-
ness of medical treatments. However, systematic variation in the mag-
nitude of response according to the type of placebo deliveredwould have
important implications for the interpretation of placebo-controlled trials,
and our knowledge base on this issue is weak. We aimed to determine
whether different types of placebos employed in knee osteoarthritis (OA)
trials are associatedwith different effect sizes, and to quantify the impact
of this difference on the estimates of treatment effects.
Methods: We searched Medline, EMBASE, Web of Science, and
Cochrane Database from inception to November 2013 with no language
restrictions, and actively sought unpublished data. We included RCTs
conducted in adults with knee OA comparing widely used pharma-
ceuticals (acetaminophen, non-selective NSAIDs, COX-2 selective
NSAIDs, topical NSAIDs, intra-articular (IA) corticosteroids, and IA
hyaluronic acid) against the following placebos: oral placebo, IA pla-
cebo, topical placebo and oralþtopical placebo. We calculated stand-
ardized mean differences (SMD) for pain at 12-week follow-up. We
performed network meta-analysis using a Bayesian random effects
model with non-informative priors. We also assessed the effect of
ignoring differential placebo responses on apparent treatment effects
by comparing our results with a network that assumes that all placebos
are the same (Figure 1).single placebo effect network.
